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As life expectancy increases, elderly populations tend to spend an increasing number of years in poor health, with chronic age-
related diseases and disability. Therefore, the development of therapeutic strategies to treat or prevent multiple
pathophysiological conditions in the elderly may improve health-adjusted life expectancy and alleviate the potential economic
and social burdens arising from age-related diseases. Bioactive natural products might represent promising new drug candidates
for the treatment of many chronic age-related diseases, including cancer, Alzheimer’s disease, cardiovascular disease, obesity,
and liver disease. Here, we discuss a therapeutic option using saikosaponins, which are triterpene saponins isolated from
Bupleurum, against a variety of age-related diseases. Understanding the underlying mechanisms of natural products like
saikosaponins in the treatment of age-related diseases may help in the development of diverse natural product-derived
compounds that may be eﬀective against a number of chronic health problems.
1. Introduction
As the average lifespan increases, as a result of improved liv-
ing standards, there is greater concern regarding health-
adjusted life expectancy. Unfortunately, health-adjusted life
expectancy has not reached longevity, which means the prev-
alence of age-related diseases such as cancer, Alzheimer’s dis-
ease (AD), cardiovascular disease, diabetes, and liver disease
is likely to increase in the future. These diseases usually cause
physiologic deterioration and resultant morbidity and mor-
tality at an advanced age. Therefore, therapeutic strategies
to intervene in chronic age-related diseases are important
for achieving a healthy old age. With the aim of prolonging
healthy aging or postponing biological aging, a variety of
approaches are being used to develop eﬀective methods for
the treatment or prevention of age-related diseases. Because
aging and age-related disease are believed to go hand in hand,
drugs and/or trials to treat or prevent chronic age-related dis-
eases might extend health-adjusted life expectancy. Oxidative
stress and inﬂammation are involved in the common patho-
logical features of age-related diseases.
Natural products can play an important role in the devel-
opment of new drugs as they may have advantages over con-
ventional chemical compound-based medications, such as
fewer side eﬀects, less long-term toxicity, variable bioavail-
ability, and unidentiﬁed chemical structures and biological
activities. Bioactive natural products are derived from vari-
ous sources including plants, animals, marine organisms,
and microorganisms. Plant-derived natural products have
been the primary materials for the treatment of diseases.
Almost every part of the plant, including the leaf, ﬂower,
bark, pod, fruit, seed, and root, can be exploited for drug
development. Natural products can be classiﬁed as alkaloids,
carbohydrates, glycosides, terpenoids, steroids, and pheno-
lics. Saikosaponins are triterpene saponin glycosides derived
from the traditional oriental medicinal plant, Bupleuri Radix,
which has been widely used for its antioxidant, anti-inﬂam-
matory, antipyretic, and antihepatotoxic eﬀects in the treat-
ment of inﬂuenza, fever, hepatitis, malaria, and menstrual
disorders [1–5]. Previous research has shown that saikosapo-
nins exhibit a variety of pharmacological activities including
antioxidant, anti-inﬂammatory, antibacterial, antiviral, and
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anticancer eﬀects [6–10]. To date, more than 100 saikosapo-
nins have been identiﬁed.
Although natural product-based drug development is
expected to be helpful for the prevention and treatment of
various chronic degenerative diseases, there is insuﬃcient
information on the underlying mechanisms of natural prod-
ucts in the body. In this review, we discuss the therapeutic
implications of saikosaponins for the treatment of diﬀerent
types of age-related diseases (Figure 1). Due to their relatively
profound founding and publishment, we discuss the thera-
peutic implications of the use of saikosaponins in cancer
treatment in greater detail.
2. Therapeutic Approaches for Cancer
Cancer is the leading cause of death worldwide. Over several
decades, many natural product-based drugs have been devel-
oped for cancer treatment, making up more than 60% of
anticancer agents. Natural product-based anticancer agents
can be used as a single agent or as an adjuvant with chemo-
therapy or radiotherapy. Among the saikosaponins, saikosa-
ponin a (SSa), saikosaponin b (SSb), and saikosaponin d
(SSd) have been shown to be anticancer agents. Compared
with their anticancer activity, the possible role of saikosapo-
nins in combating carcinogen-induced carcinogenesis has
not been well studied. However, the protective eﬀect of SSd
on diethylinitrosamine-induced liver carcinogenesis has
been reported [11]. Diethylinitrosamine-treated Sprague
Dawley rats show histopathological features of putative pre-
neoplastic lesions, such as liver nodule formation, tumor
invasion of nearby organs, and increased cellular atypia.
Interestingly, intraperitoneal injection of SSd remarkably
reduced these lesions. SSd also lowers the expression of
cyclooxygenase-2 (Cox-2) and CCAAT/enhancer binding
protein β (C/EBPβ), both of which are induced by diethyli-
nitrosamine. These results suggest that SSd prevents
diethylinitrosamine-induced liver carcinogenesis in rats via
the downregulation of Cox-2 and C/EBPβ and that SSd
might be a novel chemopreventive agent against chemical-
induced liver carcinogenesis.
SSa is a major bioactive compound of saikosaponins.
SSa-induced anticancer activity has been well reported
[12–19]. SSa has been shown to inhibit hepatoma cell
growth and DNA synthesis [12, 14–16]. Given that mRNA
and protein expression of the cyclin-dependent kinase
(Cdk) inhibitors p15 and p16, but not of the Cdk inhibi-
tors p21 or p27, are induced by SSa and that phosphory-
lation of extracellular signal-regulated kinase (Erk) is
induced by SSa [15, 16], SSa-induced inhibition of hepa-
toma cell growth might be associated with the expression
of p16 family proteins and the phosphorylation of Erk.
Furthermore, pretreatment with PD98059, an inhibitor of
MEK, an upstream kinase of Erk, prevents SSa-triggered
inhibition of hepatoma cell growth and the accompanying
induction of p15 and p16 [16], indicating that activation
of Erk and the downstream induction of p16 family pro-
teins are critical for SSa-induced inhibition of hepatoma
growth. SSa also exhibits anticancer activity in breast can-
cer. SSa inhibits the proliferation or viability of human
breast cancer cells by triggering apoptosis [17]. It induces
apoptosis in MCF-7 (wild-type p53) cells through a p53-
p21-dependent pathway and in MDA-MB-231 (mutant
p53) cells through a p53-p21-independent pathway. In
addition, SSa can induce the diﬀerentiation of rat C6 gli-
oma cells into astrocytes and/or oligodendrocytes [13].
Our group has been investigating the therapeutic implica-
tions of SSa in colon cancer. We have found that SSa-
induced cytotoxicity is greater in human colon cancer cells
compared with other cancer cells, including lung cancer,
breast cancer, and leukemia, indicating that SSa can trigger
apoptotic cancer cell death in a cell type-dependent man-
ner [19]. We also demonstrated that sequential activation
of caspase-4, 2, and 8 is critical for SSa-induced caspase-
3 activation and apoptosis in human colon cancer cells
and that caspase-4 acts upstream of SSa-induced DNA
damage [18, 19]. Given that SSa-induced apoptosis is spe-
ciﬁc to certain types of cancer, including colon cancer,
care should be taken when SSa is used as a therapeutic
tool in cancer treatment.
SSb is also a natural terpenoid. Among SSbs, saikosapo-
nin b2 (SSb2) appears to exhibit anticancer activity, espe-
cially against melanoma. In B16 melanoma cells, a relatively
high concentration of SSb2 (60–100μM) induces apoptosis,
while chronic (30 days) low-dose SSb2 (5μM) induces diﬀer-
entiation rather than apoptosis [20, 21]. Interestingly, phor-
bol 12-myristate 13-acetate (PMA), a protein kinase C
(PKC) activator, markedly inhibits both high-concentration
SSb2-induced apoptosis and low-concentration SSb2-
induced diﬀerentiation, suggesting that SSb2 exerts its anti-
cancer activity by downregulating PKC activity. Given that
a relatively high concentration of SSb2 is required to trigger
apoptosis, SSb appears to be less eﬀective against cancer cells
compared with SSa and SSd.
SSd is also a triterpene saponin found in Bupleurum
that exhibits a variety of pharmacological activities. Due
to its diverse actions, a number of studies investigating
SSd compared with other saikosaponins have been per-
formed, especially in cancer research. The anticancer activ-
ity of SSd has been broadly investigated for a variety of
cancer types, including hepatoma, glioma, melanoma,
and lung, thyroid, and prostate cancers [12, 13, 22–31].
First, SSd exerts its anticancer eﬀects against hepatoma
cells through induction of caspase-3-dependent and inde-
pendent apoptosis [22, 23], induction of p53-p21-
mediated G1 phase arrest [23], downregulation of key reg-
ulators of cancer progression [25], and downregulation of
the signal transducer and activator of transcription 3-
(STAT3-) hypoxia inducible factor- (HIF-) 1α-Cox-2 path-
way [29]. Second, like SSa, SSd can also induce the diﬀer-
entiation of rat C6 glioma cells into astrocytes [13].
However, unlike SSa, SSd cannot induce the diﬀerentiation
of C6 glioma cells into oligodendrocytes. Third, SSd
inhibits A549 lung cancer cell growth by inducing apo-
ptosis and G1 phase arrest [24]. Enhanced expression of
p53, p21, Bax, Fas, and Fas ligand appears to be the
underlying mechanism of the anticancer eﬀects of SSa
in lung cancer, especially in nonsmall cell lung cancer.
Fourth, SSd inhibits proliferation of human undiﬀerentiated
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(anaplastic) thyroid carcinoma cells through p53-p21-
mediated G1 phase arrest and Bcl-2 family-mediated
apoptosis [27]. Fifth, SSd inhibits proliferation of human
prostate cancer cells through p53-p21-mediated G1 phase
arrest and Bcl-2 family-mediated mitochondrial apoptosis
[28]. SSd also inhibits the growth and colony formation
of prostate cancer cells by reversing the epithelial-
mesenchymal transition and metastasis and by suppressing
cancer stem cell phenotypes such as self-renewal [31].
Finally, SSd nanoparticles exhibit antimelanoma activity
[30]. The activation of mitogen-activated protein kinases
(MAPKs; p38 and c-Jun N-terminal kinase (JNK)) and p53
and cytosolic release of cytochrome c are involved in SSd
nanoparticle-mediated antimelanoma activity. To date, SSd
is the most potent compound with antimelanoma activity.
SSd can also induce autophagic cell death, especially in
apoptosis-defective cells. For example, SSd induced autoph-
agy through theCa2+-calcium/calmodulin-dependent protein
kinase- (CAMKK-) AMP-activated protein kinase- (AMPK-)
mammalian target of rapamycin (mTOR) pathway in
HeLa and MCF-7 cells [26]. SSd can also cause the disrup-
tion of calcium homeostasis and resultant endoplasmic
reticulum stress, representing another mechanism of
autophagy induction in the same cancer cell lines. There-
fore, SSd might also be a promising autophagy-regulating
anticancer agent for targeting apoptosis-defective or
apoptosis-resistant cancer cells.
The development of multidrug resistance (MDR) is a
major obstacle in successful cancer chemotherapy. P-
glycoprotein (P-gp), a transmembrane multidrug transporter
capable of pumping many drugs out of cells and thus decreas-
ing eﬀective intracellular drug concentrations, is widely con-
sidered an important player in MDR. Both SSa and SSd
appear to induce the reversal of P-gp-mediated MDR. SSa
can increase the chemosensitivity of P-gp-overexpressing
HepG2/adriamycin (ADR) and MCF-7/ADR MDR cancer
cells to doxorubicin, vincristine, and paclitaxel by promoting
apoptosis, increasing the retention of drugs, and reducing P-
gp expression [32]. SSd can also increase the cytotoxicity of
doxorubicin in MCF-7/ADR cells by inhibiting P-gp-
mediated drug eﬄux, restoring drug accumulation, and
downregulating P-gp expression [33]. Moreover, SSd can
enhance the eﬃcacy of doxorubicin in MCF-7/ADR xeno-
graft mouse models as well as cell culture models without
altering the pharmacokinetic proﬁles of doxorubicin [34].
Thus, both SSa and SSd may be further developed as potent
reversal agents for P-gp-mediated MDR in cancer therapy.
Consistent with the ability of both SSa and SSd to reverse
MDR in preclinical models, SSa and SSdmight sensitize resis-
tant cancer cells to chemotherapy or radiotherapy. Both SSa
and SSd can sensitize various types of cancer cells, including
cervical, ovarian, and nonsmall cell lung, to cisplatin-
induced cell death [35]. SSa- and SSd-mediated sensitization
is accompanied by an increase in reactive oxygen species
(ROS) and an increase in caspase activation. Tumor necrosis
factor- (TNF-) α, a multifunctional proinﬂammatory cyto-
kine, can induce apoptotic cell death of certain types of
cancer. However, TNF-α-induced activation of the
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Figure 1: The use of saikosaponins and implications for age-related diseases. Several types of saikosaponins, such as saikosaponin a (SSa),
saikosaponin b (SSb), saikosaponin c (SSc), and saikosaponin d (SSd), could be used to treat age-related diseases. SSa, SSb, and SSd may
be used for the treatment of cancer as single anticancer or adjuvant agents. Inhibitory actions of saikosaponins against P-glycoprotein-
mediated multidrug resistance are implicated in the ability of saikosaponins to sensitize cancer cells to chemotherapy or radiotherapy. SSc
has dual eﬀects on human Alzheimer’s disease by targeting both tau and amyloid beta. SSa may slow or reverse the progression of
atherosclerosis by inhibiting oxidized low-density lipoprotein-induced activation of p38 and the c-Jun N-terminal kinase mitogen-
activated protein kinase pathway and assembly of the NLR family pyrin domain containing 3 inﬂammasome. SSa exerts antiobesity
activity by acting as a 5-hydroxytryptamine 2C receptor agonist or by suppressing extracellular signal-regulated kinase/nuclear factor-
(NF-) κB pathway-induced inﬂammation. SSd provides protection against diabetic nephropathy through the upregulation of Sirt3
followed by mitochondrial antioxidant enzymes like isocitrate dehydrogenase 2 and manganese-dependent superoxide dismutase. SSa, SSc,
and SSd may be used for the treatment of inﬂammatory disorders, such as asthma, arthritis, and sepsis, by downregulating the NF-κB
signaling pathway or inhibiting vascular injury/apoptosis. Lastly, SSa and SSd protect the liver against age-associated injury and ﬁbrosis by
suppressing cytokines, including platelet-derived growth factor and transforming growth factor-β1.
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transcription factor nuclear factor- (NF-) κB and NF-κB-
driven expression of prosurvival factors is a major obstacle
to preventing the cancer therapeutic eﬃcacy of TNF-α.
Therefore, inhibiting the activation of NF-κB may improve
the eﬃcacy of TNF-α. SSd enhances TNF-α-mediated apo-
ptosis by suppressing TNF-α-induced NF-κB activation and
the expression of its target prosurvival genes implicated in
cancer cell proliferation, invasion, angiogenesis, and metasta-
sis [36]. SSb can sensitize etoposide-induced apoptotic cell
death in murine B16F10 melanoma cells by suppressing
NF-κB activation and inducing DNA damage [37]. The
radiosensitizing activity of SSd has also been well reported
in human hepatoma cells [38–40]. SSd increases the radiosen-
sitivity of smmc-7721 hepatoma cells by inducing G0/G1
arrest in conditions of oxia and hypoxia [38]. SSd-mediated
radiosensitization is accompanied by the upregulation of
p53 and Bax and the downregulation of Bcl-2 in conditions
of oxia and hypoxia [38, 39]. In particular, the SSd-
mediated decrease in HIF-1α expression is critical for the
eﬀect of SSd on p53, Bax, and Bcl-2 in hypoxic conditions.
SSd-mediated radiosensitization in hypoxia is also correlated
with increased apoptosis [39]. Furthermore, the in vivo radio-
sensitizing activity of SSd was conﬁrmed with subcutaneous
smmc-7721 nude mouse xenografts [39]. SSd can also
enhance radiation-induced DNA damage and, more impor-
tantly, upregulate the level of antioxidants following radiation
treatment, indicating another beneﬁcial eﬀect of SSd [40].
Taking these ﬁndings into account, SSa and SSd can be used
as adjuvant therapies together with chemotherapy or radio-
therapy to enhance the therapeutic eﬀect.
The structures of saikosaponins can be elucidated by
comprehensive spectroscopic and chemical analysis. A
novel spectroscopic approach has been developed to
understand structure-activity relationships (SAR) more
fully. SAR studies have shown that SSa and SSd, but not
SSc, possess signiﬁcant anti-inﬂammatory activities. In
cancer therapy, SAR results suggest that the 13,28-epoxy
bridge, in which C-28 can be a methylene, a hydroxy-
methylene, or a carbonyl group, is important for the selec-
tivity and cytotoxicity of saikosaponins [41]. SAR studies
also indicate that the spatial orientation of the hydroxyl
group and the type of sugar unit are important for eﬀec-
tive cancer therapeutic action by saikosaponins.
Although SSa, SSb, and SSd have been shown to exhibit
antitumor activity, it is unlikely that all saikosaponins will
be useful in cancer treatment. The results to date suggest that
SSc is not suitable for cancer therapy, as it does not aﬀect can-
cer cell growth. Instead, SSc may have the potential for ther-
apeutic angiogenesis. For example, SSc induces human
umbilical vein endothelial cell (HUVEC) growth, migration,
and capillary tube formation [42]. Molecular signaling com-
ponents, such as matrix metalloproteinase-2, vascular endo-
thelial growth factor, and Erk, which are important in
endothelial cell growth, migration, and angiogenesis, are also
induced by SSc. We also found that SSc is less cytotoxic than
other saikosaponins (unpublished data). Various approaches
for using saikosaponins as a single modality or as an adjuvant
for cancer therapeutic purposes are summarized in Tables 1
and 2, respectively.
3. Therapeutic Approaches for Dementia
Dementia is caused by disorders that aﬀect brain func-
tion, such as memory, language, and learning. AD and
vascular dementia are the most common types of
dementia. AD is a progressive neurodegenerative disorder
that causes the loss of intellectual and social skills
including orientation, behavior, memory, thinking, and
judgment. A combination of genetic, lifestyle and envi-
ronmental factors inﬂuences the development and pro-
gression of AD. Brains from patients with AD are
characterized by brain shrinkage (atrophy), which aﬀects
nearly all functions, including memory and thinking.
The presence of tangles composed of phosphorylated
tau and senile plaques composed of amyloid beta (Aβ)
peptide, a metabolite of the sequential cleavage of amy-
loid precursor protein, is the neuropathological hallmark
of AD.
Recently, we identiﬁed SSc as a potential natural com-
pound to target both tau and Aβ [43]. Speciﬁcally, SSc
inhibits the secretion of Aβ1–40 and Aβ1–42 and abnormal
tau phosphorylation at multiple AD-related sites. Further-
more, SSc exerts beneﬁcial eﬀects on normal cellular tau
function, accelerating nerve growth factor-mediated neur-
ite outgrowth and promoting the assembly of microtu-
bules. Together, these results indicate that SSc might be
a novel therapeutic tool for treating human AD. The
therapeutic activity of SSc in other forms of dementia,
such as vascular dementia, has not been assessed.
4. Therapeutic Approaches for
Cardiovascular Diseases
Cardiovascular diseases (CVDs) refer to a class of diseases
that involve the heart and blood vessels, including coro-
nary artery diseases (e.g., angina and myocardial infarc-
tion), stroke, heart failure, hypertensive heart disease, and
other conditions aﬀecting the cardiovascular system. The
development of CVDs is associated with multiple risk fac-
tors. In East Asian countries, several natural products or
derivatives have been used as traditional oriental herbal
medicines to treat CVDs.
The therapeutic beneﬁt of saikosaponins against athero-
sclerosis has been reported [44, 45]. Saikosaponins can
inhibit oxidized low-density lipoprotein- (ox-LDL-) induced
HUVEC injury and apoptosis by inhibiting the inﬂamma-
tory response and oxidative stress [44]. Ox-LDL increases
the level of inﬂammatory cytokines (TNF-α and interleukin-
(IL-) 6), adhesion molecules (intercellular adhesion
molecule-1 and vascular cell adhesion protein-1), and mal-
ondialdehyde (MDA) and reduces the activity of superoxide
dismutase (SOD), all of which are signiﬁcantly inhibited by
saikosaponins. These antiatherosclerotic eﬀects of saikosa-
ponins are dependent on the inhibition of p38 and the
JNK MAPK signaling pathway. Among the saikosaponins,
SSa appears to be a major bioactive component involved in
antiatherosclerosis activity. SSa attenuates ox-LDL-induced
lipid uptake and promotes cholesterol eﬄux to inhibit foam
cell formation, a hallmark of early atherosclerosis [45].
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Concomitantly, SSa enhances the expression of ATP-
binding cassette transporter A1 and peroxisome
proliferator-activated receptor γ, both of which can protect
against atherosclerosis and slow the progression of athero-
sclerosis. Mechanistically, SSa inhibits ox-LDL-induced acti-
vation of Akt and NF-κB, assembly of the NLR family pyrin
domain containing 3 (NLRP3) inﬂammasome, and the con-
sequent release of inﬂammasome-dependent cytokines.
These results suggest that SSa has therapeutic potential
against atherosclerosis by modulating the PI3K/Akt pathway
and the NLRP3 inﬂammasome.
Platelet aggregation induced by collagen, thrombin,
and adenosine diphosphate (ADP) can lead to abnormal
clotting and increase the risk of CVD such as heart attack
and stroke via thrombotic and atherogenic mechanisms.
Thromboxane is known to play an important role in plate-
let activation and coagulation following thrombin activa-
tion. SSa signiﬁcantly inhibits ADP-induced platelet
aggregation and platelet thromboxane formation from ara-
chidonic acid [46]. The inhibitory eﬀect of SSa on platelet
activation indicates the therapeutic beneﬁt of SSa in the
maintenance of vascular homeostasis.
Table 1: Therapeutic strategies for cancer using saikosaponins. Related references are listed.
Saikosaponins Mode of action Target molecules Cancer model Ref.
SSa
Growth inhibition Not determined Liver cancer [12]
Diﬀerentiation Not determined Glioma [13]
Increase in sub-G1 peak Not determined Liver cancer [14]
G1 phase arrest p15, p16 Liver cancer [15]
G1 phase arrest Erk, p15, p16 Liver cancer [16]
Apoptosis Bcl-2, c-Myc, p53, p21 Breast cancer [17]
Apoptosis Caspase-2, Caspase-8 Colon cancer [18]
Apoptosis, DNA damage Caspase-4, Caspase-2 Colon cancer [19]
SSb
G1 phase arrest PKC Melanoma [20]
Diﬀerentiation PKC Melanoma [21]
SSd
Growth inhibition Not determined Liver cancer [12]
Diﬀerentiation Not determined Glioma [13]
Apoptosis Not determined Liver cancer [22]
G1 phase arrest, apoptosis p53, p21, Bax, Fas (L), NF-κB Liver cancer [23]
G1 phase arrest, apoptosis p53, p21, Bax, Fas (L) Lung cancer [24]
Inhibition of invasiveness and metastasis MMP-2, MMP-13, TIMP-2 Liver cancer [25]
Autophagic cell death CAMKK, AMPK, mTORC Apoptosis-resistant cancer [26]
G1 phase arrest, apoptosis p53, p21, Bax, Bcl-2 Undiﬀerentiated thyroid cancer [27]
G1 phase arrest, apoptosis p53, p21, Bcl-2, cytochrome c Prostate cancer [28]
Apoptosis STAT3, HIF-1a, Cox-2 Liver cancer [29]
Apoptosis JNK, p38, p53, cytochrome c Melanoma [30]
Inhibition of invasiveness, metastasis, stemness GSK3β, Wnt/β-catenin Prostate cancer [31]
Table 2: Therapeutic strategies for improving sensitivity to chemotherapy and radiotherapy with the use of saikosaponins in cancer therapy.
Related references are listed. DOX: doxorubicin; VCR: vincristine; PAC: paclitaxel; CDDP: cisplatin; ET: etoposide; IR: ionizing radiation;
GSH: glutathione; MDA: malondialdehyde.
Saikosaponins Therapy Mode of action Target molecules Cancer model Ref.
SSa
DOX, VCR, PAC Apoptosis P-gp MDR breast & liver cancer [32]
CDDP Apoptosis ROS Cervical & ovarian & lung cancer [35]
SSb ET Apoptosis, DNA damage NF-κB Melanoma [37]
SSd
DOX Cytotoxicity P-gp MDR breast cancer [33]
DOX Cytotoxicity P-gp MDR breast cancer [34]
CDDP Apoptosis ROS Cervical & ovarian & lung cancer [35]
TNF-α Apoptosis NF-κB Cervical & liver cancer [36]
IR G1 phase arrest, apoptosis p53, Bax, Bcl-2 Liver cancer [38]
IR Apoptosis HIF-1α, p53, Bax, Bcl-2 Liver cancer [39]
IR DNA damage GSH, MDA Liver cancer [40]
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5. Therapeutic Approaches for Obesity
Obesity is a common and growing public health problem in
modern life, and eﬀective treatment is challenging. Obesity
results in an increased mortality rate and signiﬁcant health
problems, including type 2 diabetes, hypertension, heart dis-
ease, stroke, hyperlipidemia, asthma, and certain types of
cancer. However, the role of drug therapy in the comprehen-
sive care of patients with obesity has been questioned. Most
obesity drugs have both eﬃcacy and safety issues. Long-
term medication is limited in its eﬀects on weight loss, and
most patients regain weight once the use of obesity drugs is
stopped. Abundant natural products have been explored for
their potential to treat obesity, which could provide an excel-
lent alternative strategy for the management of obesity.
Recently, the antiobesity action of saikosaponins has
been reported [47, 48]. Modulating 5-hydroxytryptamine
2C (5-HT 2C) appears to be an important strategy for the
treatment of obesity because the central 5-HT system is crit-
ical for the brain’s control of energy homeostasis, and human
obesity is associated with a diminished biosynthesis and
chronic turnover of 5-HC in the brain. Saikosaponins exhibit
agonistic activity on the 5-HT 2C receptor, thereby exerting
antiobesity properties [47]. SSa appears to be the biologically
active compound with antiobesity properties, with obvious
agonistic activity on the 5-HT 2C receptor. SSa can also
attenuate obesity-associated inﬂammation in hypertrophied
3T3-L1 adipocytes via the Erk/NF-κB pathway [48]. Finally,
SSa signiﬁcantly decreases proinﬂammatory cytokines, such
as TNF-α and IL-1β, and inﬂammatory factors, such as
inducible nitric oxide synthase (iNOS) and Cox-2, by inhibit-
ing the NF-κB pathway in 3T3-L1 adipocytes. Given that pre-
treatment with U0126, an Erk inhibitor, inhibits nuclear
translocation of NF-κB, the antiobesity action of SSa appears
to be mediated by reduced inﬂammation via the downregula-
tion of Erk following NF-κB inhibition.
6. Therapeutic Approaches for Diabetes
Diabetes mellitus, which is commonly referred to as diabetes,
is a chronic metabolic disorder in which high blood glucose
levels are present in the body over a prolonged period due
to defects in the production and/or function of insulin.
Although diabetes may not be a normal part of aging and
type 1 diabetes can occur at any age, the incidence of type 2
diabetes, which is more common than type 1, increases with
age and is usually seen in middle-aged or older individuals.
Diabetes can damage both large and small blood vessels,
thereby increasing the risk of heart attack, stroke, blindness,
and kidney disease. In the treatment of diabetes, the eﬃcacy
of antidiabetics varies for each individual, indicating that
more individual-speciﬁc diabetic treatment is needed. This
may be because many antidiabetics work on only one or
two causes of the disease. Side eﬀects also present a signiﬁ-
cant problem as some antidiabetics cause side eﬀects such
as low blood glucose and/or weight gain.
Diabetes is a major risk factor for kidney disease because
diabetes can damage the kidney. Diabetic kidney disease, also
known as diabetic nephropathy, is the chronic loss of kidney
function that occurs in diabetes mellitus over a patient’s life-
time. SSd protects renal tubular epithelial cells against high
glucose-induced diabetic nephropathy [49]. High glucose
levels result in the production of highly reactive compounds
(e.g., ROS and MDA), as well as a concomitant decrease in
the activity of antioxidant enzymes (e.g., SOD) in renal tubu-
lar epithelial cells. Incubation with SSd signiﬁcantly restores
these changes via the upregulation of mitochondrial NAD-
dependent deacetylase Sirt3 expression followed by the
upregulation of the expression of mitochondrial NADP-
dependent isocitrate dehydrogenase 2 and manganese-
dependent SOD.
7. Therapeutic Approaches for Inflammation
Inﬂammation is triggered by the innate immune system as
a defense mechanism against infection or tissue injury.
However, the transition from transient and/or acute
inﬂammation to chronic inﬂammation triggered by the
dysregulation of the normal immune response leads to
inﬂammatory disorders such as asthma, arthritis, and
autoimmune diseases. Inﬂammation appears to be related
to nearly every chronic disease, including cancer, demen-
tia, cardiovascular diseases, and diabetes.
Saikosaponins are well known for their immunomodula-
tory antiallergic inﬂammation action [50]. SSd suppresses
murine T lymphocyte activation [51], indicating that SSd
may be a potential candidate for the treatment of autoreac-
tive T lymphocyte-mediated autoimmune diseases. The
inhibitory eﬀects of SSd on PMA-triggered T lymphocyte
activation are associated with SSd-induced downregulation
of NF-κB, nuclear factor of activated T-cells, and activator
protein-1 (c-Fos) signaling pathways. SSd is also eﬀective in
the treatment of allergic reactions induced by β-conglycinin
[52]. SSd inhibits β-conglycinin-induced activation and
degranulation of rat basophilic leukemia-2H3 cells by sup-
pressing intracellular mobilization and tyrosine phosphory-
lation followed by suppression of ROS generation,
activation of Cdc42 and c-Fos, and β-hexosaminidase
release. Because soybean β-conglycinins are potential food
allergens, SSd might be an eﬀective therapy for alleviating
soybean allergy. Both SSa and SSd exhibit anti-
inﬂammatory activity. iNOS and Cox-2 play pivotal roles in
the development of certain inﬂammatory conditions, and
modulating iNOS and Cox-2 is thought to be a promising
therapeutic tool to inhibit inﬂammation. Both SSa and SSd
inhibit the production of iNOS-derived nitric oxide and
Cox-2-derived prostaglandin E2 triggered by lipopolysaccha-
ride (LPS) in murine macrophage RAW264.7 cells [53]. The
LPS-induced production of proinﬂammatory cytokines, such
as TNF-α and IL-6, is also suppressed by SSa and SSd. All of
the inhibitory eﬀects of SSa and SSd have been attributed to
the cytosolic retention of NF-κB in RAW264.7 cells. More-
over, these saikosaponins have been shown to exhibit signif-
icant in vivo anti-inﬂammatory activity in two diﬀerent
murine models; a rat model of carrageenan-induced paw
swelling and a mouse model of acetic acid-induced vascular
permeability. Remarkably, these saikosaponins appear to be
useful in the treatment of inﬂammatory diseases. For
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instance, SSa can exert inhibitory activity against a rat model
of allergic asthma, a complex and chronic inﬂammatory dis-
order [54], and against inﬂammatory arthritis in a human
osteoarthritis chondrocyte cell model [55]. These ﬁndings
suggest that saikosaponins may be used in anti-
inﬂammatory treatment strategies for chronic disease.
Sepsis, a life-threatening body-wide complication of
infection, occurs through blood-borne infection with micro-
organisms such as bacteria, fungi, or viruses. Administration
of small doses of bacterial LPS to mice triggers acute inﬂam-
mation and endothelial damage and apoptosis, mimicking
the early stages of septic shock in humans. We recently dem-
onstrated that SSc inhibits LPS-induced apoptosis by inhibit-
ing caspase-3 activation and the subsequent degradation of
focal adhesion kinase in endothelial HUVECs [56]. Our
results suggest that SSc represents a promising therapeutic
candidate for the treatment of vascular endothelial cell injury
and barrier dysfunction.
8. Therapeutic Approaches for Liver Disease
Consistent with the fact that aging aﬀects the liver to a lesser
degree than other organs and that there are no identiﬁed
liver diseases speciﬁc to advanced age, there have been few
comprehensive studies of liver degeneration during the
aging process. Nonetheless, liver function decreases and liver
damage increases with age. Acute liver injury has been
shown to be greater in aged rats compared with younger rats
[57, 58]. In a mouse liver model, age-related repression of
three key regulators of liver function, C/EBPα, farnesoid X
receptor, and telomerase reverse transcriptase, may lead to
an increase in liver injury and apoptosis following carbon
tetrachloride (CCl4) treatment [59]. Liver ﬁbrosis is a conse-
quence of the excessive accumulation of extracellular matrix
(ECM) protein including collagen as a healing response trig-
gered by chronic liver injury. Aging also increases suscepti-
bility to hepatic inﬂammation and liver ﬁbrosis and
enhances the liver ﬁbrotic response by disrupting ECM
remodeling. Stellate cells are the major cell type involved in
liver ﬁbrosis. Following liver injury, hepatic stellate cells
undergo activation, leading to increased proliferation and
migration, which is responsible for the increased synthesis
and deposition of ECM proteins in the liver and for ampliﬁ-
cation of the ﬁbrotic response.
Although Bupleurum has yielded a number of pharmaco-
logically active compounds, the most relevant for the treat-
ment of liver disease is the saikosaponins. Both SSa and SSd
have been shown to improve hepatic antioxidant capacity
and protect against CCl4-induced liver injuries, such as
inﬂammation and ﬁbrosis, in rat models [8, 9, 60]. SSa and
SSd also inhibit platelet-derived growth factor (PDGF) and
transforming growth factor- (TGF-) β1-induced prolifera-
tion and migration of hepatic stellate cells [61]. Downregula-
tion of Erk/PDGF/TGF-β1 signaling has been implicated in
SSa- and SSd-mediated liver protection. Both SSa and SSd
also signiﬁcantly induce hepatic stellate cell apoptosis. Given
that survival, proliferation, and migration of hepatic stellate
cells are key drivers of liver ﬁbrosis and ECM remodeling,
SSa and SSd might exert therapeutic activities against liver
ﬁbrosis and damage by inhibiting the activation of hepatic
stellate cells.
9. Conclusions and Perspectives
Natural products, such as herbal medicines, represent
monotherapies or adjunctive therapies in the treatment
of age-related diseases. Because conventional drugs have
limitations and adverse side eﬀects, the development of
alternative medicines is necessary. Owing to the advan-
tages of natural products, additional pharmaceutical agents
will be discovered. Saikosaponins, which we have been
studying for a long time, can be developed as novel poten-
tial drugs for future therapeutic strategies. Naturally occur-
ring saikosaponins have been studied by diﬀerent research
groups and found to be very promising drug candidates
for the prevention and treatment of various age-related
diseases due to their multiple actions in inﬂammation, oxi-
dant/antioxidant balance, and damage response.
However, despite its usefulness and potential for growth,
natural product-derived medicine has not yet been widely
applied in age-related diseases. As shown above, a signiﬁcant
portion of the research on natural products, including saiko-
saponins, has focused on cancer. It is still unknown whether
saikosaponins exert therapeutic activity against other chronic
disorders such as the forms of dementia other than AD and
cardiovascular diseases other than atherosclerosis. Likewise,
the therapeutic relevance of saikosaponins in the aging pro-
cess remains unclear. Moreover, despite the extensive litera-
ture on the anticancer activities of saikosaponins, the
cytotoxicity of saikosaponins has not been well investigated
in normal cells. Therefore, it is necessary to evaluate the cyto-
toxic selectivity of saikosaponins for cancer cells versus nor-
mal cells. For research purposes, the accumulation of
scientiﬁc data through cell culture, molecular biology, and
in vivo mouse experiments will be necessary for an under-
standing of the underlying mechanisms of the therapeutic
action and toxicity of natural products like saikosaponins in
the body. Further studies of the possibly superior outcome
of saikosaponin treatment over other components of
Bupleuri Radix and the probable advantage of combined
treatment with saikosaponin monomers and other compo-
nents of Bupleuri Radix in the treatment of various age-
related diseases are also required.
Saikosaponins are minimally soluble in water. Saikosa-
ponins contain a rigid hydrophobic group and are dis-
solved in DMSO. Since DMSO may be toxic to normal
cells, there are safety concerns regarding the use of DMSO
as a solvent. However, given that less than 0.1% DMSO is
generally noninﬂuential and that the ﬁnal concentration of
DMSO as a solvent of saikosaponins can be adjusted to be
no greater than 0.1%, the possibility of DMSO toxicity in
saikosaponin solution seems very slight. Nonetheless, the
poor solubility of saikosaponins may be a major problem
in future drug development. Therefore, various approaches
to improve the solubility and bioavailability of saikosapo-
nins should be considered. The application of pharmaceu-
tical particle technologies, such as particle size reduction
technologies and bioavailability enhancement technologies
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to saikosaponins may improve their solubility and phar-
macokinetics for clinical development.
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